Compare Digital Realty Trust, Inc. (DLR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Digital Realty Trust, Inc. trades at $173.11 (market cap $65.83B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Digital Realty Trust, Inc. and Regeneron Pharmaceuticals Inc are close in size by market cap, and Digital Realty Trust, Inc. pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| DLR | REGN | |
|---|---|---|
Market Cap | $65.83B | $69.52B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $812.27 |
52-Week Low | $147.93 | $542.52 |
Enterprise Value | $83.35B | $63.47B |
Dividend Yield | 2.74% | 0.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
